MX2022006281A - Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso. - Google Patents

Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.

Info

Publication number
MX2022006281A
MX2022006281A MX2022006281A MX2022006281A MX2022006281A MX 2022006281 A MX2022006281 A MX 2022006281A MX 2022006281 A MX2022006281 A MX 2022006281A MX 2022006281 A MX2022006281 A MX 2022006281A MX 2022006281 A MX2022006281 A MX 2022006281A
Authority
MX
Mexico
Prior art keywords
compounds
delta
methods
heterocyclic compounds
desaturase inhibitors
Prior art date
Application number
MX2022006281A
Other languages
English (en)
Inventor
Jennifer R Allen
Matthew P Bourbeau
Iain Lingard
Michela Beltrani
Teodora P Damyanova
Ana E Minatti
Paolo Vincetti
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022006281A publication Critical patent/MX2022006281A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona compuestos útiles para la inhibición de Delta-5 Desaturasa ("D5D"). Los compuestos tienen una fórmula general I: (ver Fórmula) en la que las variables de Fórmula I se definen en la presente. Esta divulgación también proporciona composiciones farmacéuticas que comprenden los compuestos, usos de los compuestos y composiciones para el tratamiento de, por ejemplo, un trastorno metabólico o cardiovascular. Además, la divulgación proporciona productos intermedios útiles en la síntesis de compuestos de Fórmula I.
MX2022006281A 2019-11-25 2020-11-24 Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso. MX2022006281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
MX2022006281A true MX2022006281A (es) 2022-06-08

Family

ID=73855555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006281A MX2022006281A (es) 2019-11-25 2020-11-24 Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.

Country Status (19)

Country Link
US (3) US11512097B2 (es)
EP (1) EP4065223A1 (es)
JP (2) JP7254246B2 (es)
KR (2) KR20230154292A (es)
CN (2) CN118161500A (es)
AR (1) AR120556A1 (es)
AU (1) AU2020392087A1 (es)
BR (1) BR112022010054A2 (es)
CA (1) CA3162281A1 (es)
CL (2) CL2022001357A1 (es)
CO (1) CO2022008690A2 (es)
CR (1) CR20220308A (es)
IL (1) IL293191A (es)
JO (1) JOP20220125A1 (es)
MX (1) MX2022006281A (es)
PE (1) PE20231097A1 (es)
TW (2) TWI815061B (es)
UY (1) UY38971A (es)
WO (1) WO2021108408A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022006281A (es) 2019-11-25 2022-06-08 Amgen Inc Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法
WO2024112763A1 (en) 2022-11-23 2024-05-30 Amgen Inc. Selection of patients for the treatment of fads1-mediated diseases or disorders using fads-1 inhibitors

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE3786365T2 (de) 1986-04-07 1993-10-21 Kumiai Chemical Industry Co 5H-1,3,4-Thiadiazolo[3,2-a]pyrimidin-5-on-Derivate und diese enthaltende Gartenbau- und landwirtschaftliche Fungizidmittel.
CZ9902016A3 (cs) 1996-12-05 1999-11-17 Amgen Inc. Substituované pyrimidinonové a pyridonové sloučeniny a způsoby jejich použití
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
MXPA02003614A (es) 1999-10-15 2002-10-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de ganadotropina y metodos relacionados con los mismos..
WO2003106435A1 (en) 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
AR049769A1 (es) 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
CA2612585A1 (en) 2005-06-27 2007-01-04 Amgen Inc. Anti-inflammatory aryl nitrile compounds
EP1905238A4 (en) 2005-07-18 2009-04-22 Samsung Electronics Co Ltd VIDEO CODING METHOD AND DEVICE FOR INCREASING CONFORMITY BETWEEN ENCODERS AND DECODERS
US20080214395A1 (en) 2005-07-27 2008-09-04 Basf Aktiengesellschaft Fungicidal 5-Methyl-6-Phenyltriazolopyrimidinylamines
JP2009502863A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア ６−フェニル−ピラゾロピリミジン−７−イルアミン殺菌剤
BRPI0613912A2 (pt) 2005-07-27 2016-11-22 Basf Ag compostos, processo para preparar compostos, agente fungicida, semente, e, método para combater fungos nocivos fitopatogênicos
CA2627623C (en) 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
US20100029636A1 (en) 2006-09-28 2010-02-04 Peter Buehlmayer Lck inhibitors
US8173661B2 (en) 2006-11-08 2012-05-08 The Rockefeller University Alpha-IIB-beta-3 inhibitors and uses thereof
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
WO2008089307A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
CA2673992A1 (en) 2007-01-19 2008-07-24 Basf Se Fungicidal mixtures of 1-methylpyrazol-4-ylcarboxanilides and azolopyrimidinylamines
EP2131658A2 (en) 2007-01-30 2009-12-16 Basf Se Method for improving plant health
WO2008116730A1 (de) 2007-03-23 2008-10-02 Basf Se Wirkstoffkombinationen
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2274308A1 (en) 2008-04-04 2011-01-19 Gilead Sciences, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
TW201033213A (en) * 2009-01-27 2010-09-16 Takeda Pharmaceutical Fused ring compound and use thereof
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JPWO2012011592A1 (ja) 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2013177538A2 (en) 2012-05-24 2013-11-28 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
MX2015011898A (es) 2013-03-13 2016-05-05 Genentech Inc Compuestos de pirazolo y usos de los mismos.
MX2016002794A (es) 2013-09-05 2016-09-13 Genentech Inc Compuestos antiproliferativos.
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
BR112016024455B1 (pt) 2014-04-23 2023-02-07 Mitsubishi Tanabe Pharma Corporation Composto heterocíclico bicíclico ou tricíclico
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
US11414385B2 (en) 2015-12-21 2022-08-16 The University Of Chicago Compounds and methods for treating, detecting, and identifying compounds to treat apicomplexan parasitic diseases
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
MX2019002303A (es) 2016-08-31 2019-07-15 Agios Pharmaceuticals Inc Inhibidores de procesos metabolicos celulares.
CN106749271B (zh) 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
US20200360381A1 (en) 2017-05-15 2020-11-19 Dana-Farber Cancer Institute, Inc. Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
US10738056B2 (en) 2017-09-15 2020-08-11 Aduro Biotech Inc. Pyrazolopyrimidinone compounds and uses thereof
MX2022006281A (es) 2019-11-25 2022-06-08 Amgen Inc Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.

Also Published As

Publication number Publication date
KR20220106159A (ko) 2022-07-28
BR112022010054A2 (pt) 2022-08-16
CA3162281A1 (en) 2021-06-03
IL293191A (en) 2022-07-01
US11512097B2 (en) 2022-11-29
EP4065223A1 (en) 2022-10-05
US20210221824A1 (en) 2021-07-22
CN114728167B (zh) 2024-03-19
CR20220308A (es) 2022-08-04
CN114728167A (zh) 2022-07-08
JP7254246B2 (ja) 2023-04-07
JP2022549739A (ja) 2022-11-28
PE20231097A1 (es) 2023-07-18
TW202409042A (zh) 2024-03-01
KR102598203B1 (ko) 2023-11-03
US20230159560A1 (en) 2023-05-25
TWI815061B (zh) 2023-09-11
TW202132317A (zh) 2021-09-01
JOP20220125A1 (ar) 2023-01-30
CL2023002486A1 (es) 2024-01-12
AU2020392087A1 (en) 2022-06-09
JP2023078418A (ja) 2023-06-06
CO2022008690A2 (es) 2022-06-30
WO2021108408A1 (en) 2021-06-03
CL2022001357A1 (es) 2023-03-10
CN118161500A (zh) 2024-06-11
AR120556A1 (es) 2022-02-23
KR20230154292A (ko) 2023-11-07
US20210188874A1 (en) 2021-06-24
UY38971A (es) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2022006281A (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
CR20200376A (es) Inhibidores de cd73
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2023007192A (es) Inhibidores de prmt5.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
GEP20166484B (en) Protein kinase inhibitors
GEP20166443B (en) Heterocyclic compound and use thereof
MY152271A (en) Novel compounds that are erk inhibitors
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
TW200745066A (en) Novel PTP1B inhibitors
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2021009521A (es) Inhibidores de dihidroorotato deshidrogenasa.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
MX2022006370A (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso.
MX2010002042A (es) Derivados de 1,3-dihidroisoindol.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2010007543A (es) Inhibidores de iap.